[go: up one dir, main page]

WO2004078163A3 - Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen - Google Patents

Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen Download PDF

Info

Publication number
WO2004078163A3
WO2004078163A3 PCT/US2004/006288 US2004006288W WO2004078163A3 WO 2004078163 A3 WO2004078163 A3 WO 2004078163A3 US 2004006288 W US2004006288 W US 2004006288W WO 2004078163 A3 WO2004078163 A3 WO 2004078163A3
Authority
WO
WIPO (PCT)
Prior art keywords
ester
api
acid
heterocyclic ring
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/006288
Other languages
French (fr)
Other versions
WO2004078163A2 (en
Inventor
Oern Almarsson
Magali Bourghol Hickey
Matthew Peterson
Brian Moulton
Nair Rodriguez-Hornedo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
University of Michigan System
Transform Pharmaceuticals Inc
University of Michigan Ann Arbor
University of South Florida St Petersburg
Original Assignee
University of South Florida
University of Michigan System
Transform Pharmaceuticals Inc
University of Michigan Ann Arbor
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/006662 external-priority patent/WO2003074474A2/en
Priority claimed from US10/449,307 external-priority patent/US7078526B2/en
Priority claimed from PCT/US2003/019574 external-priority patent/WO2004000284A1/en
Priority claimed from PCT/US2003/027772 external-priority patent/WO2004078161A1/en
Priority claimed from US10/660,202 external-priority patent/US7927613B2/en
Priority claimed from PCT/US2003/041273 external-priority patent/WO2004061433A1/en
Priority to JP2006508979A priority Critical patent/JP2007524596A/en
Application filed by University of South Florida, University of Michigan System, Transform Pharmaceuticals Inc, University of Michigan Ann Arbor, University of South Florida St Petersburg filed Critical University of South Florida
Priority to EP04715190A priority patent/EP1631260A2/en
Priority to CA002514733A priority patent/CA2514733A1/en
Priority to US10/546,963 priority patent/US20070059356A1/en
Priority to PCT/US2004/009947 priority patent/WO2004089313A2/en
Priority to US10/551,014 priority patent/US20060223794A1/en
Priority to US10/926,842 priority patent/US7446107B2/en
Priority to JP2007500742A priority patent/JP2007525502A/en
Priority to PCT/US2004/028456 priority patent/WO2005092884A1/en
Priority to EP04782868A priority patent/EP1718640A4/en
Priority to EP20040783308 priority patent/EP1670753A4/en
Priority to JP2006525508A priority patent/JP4842819B2/en
Publication of WO2004078163A2 publication Critical patent/WO2004078163A2/en
Publication of WO2004078163A3 publication Critical patent/WO2004078163A3/en
Anticipated expiration legal-status Critical
Priority to IL173575A priority patent/IL173575A0/en
Priority to NO20060669A priority patent/NO20060669L/en
Priority to US12/234,420 priority patent/US20090088443A1/en
Priority to IL199140A priority patent/IL199140A/en
Priority to US12/792,415 priority patent/US20100311701A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphinic acid, phosphonic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, 0-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.
PCT/US2004/006288 2002-02-15 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen Ceased WO2004078163A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
US10/546,963 US20070059356A1 (en) 2002-05-31 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA002514733A CA2514733A1 (en) 2003-02-28 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2006508979A JP2007524596A (en) 2003-02-28 2004-02-26 Co-crystal pharmaceutical composition
EP04715190A EP1631260A2 (en) 2003-02-28 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US10/551,014 US20060223794A1 (en) 2002-02-15 2004-03-31 Novel olanzapine forms and related methods of treatment
PCT/US2004/009947 WO2004089313A2 (en) 2003-04-01 2004-03-31 Novel olanzapine forms and related methods of treatment
US10/926,842 US7446107B2 (en) 2002-02-15 2004-08-26 Crystalline forms of conazoles and methods of making and using the same
JP2007500742A JP2007525502A (en) 2004-02-26 2004-09-01 Novel crystalline forms of conazoles and methods for their production and use
PCT/US2004/028456 WO2005092884A1 (en) 2004-02-26 2004-09-01 Novel crystalline forms of conazoles and methods of making and using the same
EP04782868A EP1718640A4 (en) 2004-02-26 2004-09-01 Novel crystalline forms of conazoles and methods of making and using the same
EP20040783308 EP1670753A4 (en) 2003-09-04 2004-09-04 Modafinil compositions
JP2006525508A JP4842819B2 (en) 2003-09-04 2004-09-04 Modafinil composition
IL173575A IL173575A0 (en) 2003-09-04 2006-02-07 Modafinil compositions
NO20060669A NO20060669L (en) 2003-09-11 2006-02-10 Modafinilsammensetninger
US12/234,420 US20090088443A1 (en) 2002-02-15 2008-09-19 Novel crystalline forms of conazoles and methods of making and using the same
IL199140A IL199140A (en) 2003-09-04 2009-06-03 Modafinil compositions
US12/792,415 US20100311701A1 (en) 2002-02-15 2010-06-02 Pharmaceutical Co-Crystal Compositions

Applications Claiming Priority (26)

Application Number Priority Date Filing Date Title
US45121303P 2003-02-28 2003-02-28
US60/451,213 2003-02-28
USPCT/US03/06662 2003-03-03
PCT/US2003/006662 WO2003074474A2 (en) 2002-03-01 2003-03-03 Multiple-component solid phases containing at least one active pharmaceutical ingredient
US45602703P 2003-03-18 2003-03-18
US60/456,027 2003-03-18
US46396203P 2003-04-18 2003-04-18
US60/463,962 2003-04-18
US10/449,307 2003-05-30
US10/449,307 US7078526B2 (en) 2002-05-31 2003-05-30 CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
PCT/US2003/019574 WO2004000284A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution
US10/601,092 2003-06-20
USPCT/US03/19574 2003-06-20
US10/601,092 US20050025791A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution
US48706403P 2003-07-11 2003-07-11
US60/487,064 2003-07-11
PCT/US2003/027772 WO2004078161A1 (en) 2003-02-28 2003-09-04 Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
USPCT/US03/27772 2003-09-04
US10/660,202 US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions
US10/660,202 2003-09-11
US50820803P 2003-10-02 2003-10-02
US60/508,208 2003-10-02
PCT/US2003/041273 WO2004061433A1 (en) 2002-12-30 2003-12-24 Pharmaceutical compositions with improved dissolution
USPCT/US03/41273 2003-12-24
US54275204P 2004-02-06 2004-02-06
US60/542,752 2004-02-06

Related Parent Applications (6)

Application Number Title Priority Date Filing Date
PCT/US2003/006662 Continuation-In-Part WO2003074474A2 (en) 2002-02-15 2003-03-03 Multiple-component solid phases containing at least one active pharmaceutical ingredient
US10/449,307 Continuation-In-Part US7078526B2 (en) 2002-02-15 2003-05-30 CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US10/601,092 Continuation-In-Part US20050025791A1 (en) 2002-02-15 2003-06-20 Pharmaceutical compositions with improved dissolution
US10/637,829 Continuation-In-Part US20040053853A1 (en) 2002-02-15 2003-08-08 Topiramate salts and compositions comprising and methods of making and using the same
PCT/US2003/027772 Continuation-In-Part WO2004078161A1 (en) 2002-02-15 2003-09-04 Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US10/660,202 Continuation-In-Part US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/601,092 Continuation-In-Part US20050025791A1 (en) 2002-02-15 2003-06-20 Pharmaceutical compositions with improved dissolution
US10/926,842 Continuation-In-Part US7446107B2 (en) 2002-02-15 2004-08-26 Crystalline forms of conazoles and methods of making and using the same
US12/792,415 Continuation US20100311701A1 (en) 2002-02-15 2010-06-02 Pharmaceutical Co-Crystal Compositions

Publications (2)

Publication Number Publication Date
WO2004078163A2 WO2004078163A2 (en) 2004-09-16
WO2004078163A3 true WO2004078163A3 (en) 2005-01-20

Family

ID=56290526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006288 Ceased WO2004078163A2 (en) 2002-02-15 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen

Country Status (4)

Country Link
EP (1) EP1631260A2 (en)
JP (1) JP2007524596A (en)
CA (1) CA2514733A1 (en)
WO (1) WO2004078163A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9440957B2 (en) 2012-06-06 2016-09-13 Novartis Ag Compounds and compositions for modulating EGFR Activity
US9532993B2 (en) 2011-11-25 2017-01-03 Nuformix Limited Aprepitant L-proline solvates—compositions and cocrystals
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof

Families Citing this family (406)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129714A1 (en) 2001-06-22 2003-01-02 Bayer Ag Topical application of thiazolylamides
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
JP4906233B2 (en) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ Multi-component solid phase containing at least one active pharmaceutical ingredient
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
EP1670753A4 (en) * 2003-09-04 2008-01-02 Cephalon Inc Modafinil compositions
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2006007448A2 (en) * 2004-06-17 2006-01-19 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
DE102005014248A1 (en) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmaceutical preparation of N- [5- (aminosulfonyl) -4-methyl-1,3-thiazol-2-yl] -N-methyl-2- [4- (2-pyridinyl) phenyl] acetamide
CA2612384A1 (en) * 2005-06-15 2006-12-28 Elan Pharma International, Limited Nanoparticulate azelnidipine formulations
US20070099237A1 (en) * 2005-10-31 2007-05-03 The Regents Of The University Of Michigan Reaction co-crystallization of molecular complexes or co-crystals
AR057882A1 (en) 2005-11-09 2007-12-26 Novartis Ag DOUBLE ACTION COMPOUNDS OF ANGIOTENSIN RECEPTOR BLOCKERS AND NEUTRAL ENDOPEPTIDASE INHIBITORS
US8163790B2 (en) 2005-12-08 2012-04-24 New Form Pharmaceuticals, Inc. Metronidazole cocrystals and imipramine cocrystals
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20080132419A1 (en) * 2006-10-04 2008-06-05 Nair Rodriguez-Hornedo Dissolution and precipitation of cocrystals with ionizable components
BRPI0717824A2 (en) * 2006-10-10 2014-04-15 Janssen Pharmaceutica Nv (S) - (+) - 2- (2-CHLOROPHYL) -2-HYDROXY-ETHYL CARBAMATE CRYSTAL
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
TW200901889A (en) 2007-02-09 2009-01-16 Basf Se Crystalline complexes of agriculturally active organic compounds
WO2008108639A1 (en) * 2007-03-08 2008-09-12 Avantium Holding B.V. Co-crystalline forms of carbamazepine
WO2008153945A2 (en) * 2007-06-06 2008-12-18 University Of South Florida Nutraceutical co-crystal compositions
US8124603B2 (en) 2008-01-22 2012-02-28 Thar Pharmaceuticals In vivo studies of crystalline forms of meloxicam
US7935817B2 (en) 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
US8003700B2 (en) * 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
WO2009140466A2 (en) * 2008-05-14 2009-11-19 Dr. Reddy's Laboratories Ltd. Linezolid co-crystals
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
WO2009152347A2 (en) * 2008-06-13 2009-12-17 Bionevia Pharmaceuticals Inc. Crystalline forms of zotepine hydrochloride
WO2010002675A2 (en) 2008-06-30 2010-01-07 Mutual Pharmaceutical Company, Inc. Quinine sulfate/bisulfate solid complex; methods of making; and methods of use thereof
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
CA2738866A1 (en) * 2008-08-06 2010-02-11 Bionevia Pharmaceuticals, Inc. Flupirtine hydrochloride maleic acid cocrystal
WO2010028132A2 (en) 2008-09-06 2010-03-11 Bionevia Pharmaceuticals, Inc. Novel choline cocrystal of epalrestat
EP2177215A1 (en) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
EP2199274A1 (en) * 2008-12-16 2010-06-23 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and paracetamol
WO2010085589A2 (en) 2009-01-22 2010-07-29 G&H Brands Llc Desensitizing drug product
KR20100091127A (en) * 2009-02-09 2010-08-18 주식회사 한독약품 Novel salts of adefovir dipivoxil and method for the preparation of the same
JP5558875B2 (en) * 2009-03-19 2014-07-23 日本曹達株式会社 Novel inclusion complex, epoxy resin composition and epoxy resin composition for semiconductor encapsulation
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8455522B2 (en) 2009-05-15 2013-06-04 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
SI2429995T1 (en) 2009-05-15 2014-05-30 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
WO2010134085A1 (en) * 2009-05-20 2010-11-25 Institute Of Life Sciences Pharmaceutical co-crystals of quercetin
ES2523734T3 (en) 2009-05-28 2014-12-01 Novartis Ag Aminopropionic derivatives substituted as neprilysin inhibitors
JP5466759B2 (en) 2009-05-28 2014-04-09 ノバルティス アーゲー Substituted aminobutyric acid derivatives as neprilysin inhibitors
AR077490A1 (en) 2009-07-21 2011-08-31 Novartis Ag TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF A HYPERPROLIFERATIVE SKIN CONDITION
AR077328A1 (en) 2009-07-24 2011-08-17 Novartis Ag DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
KR101813728B1 (en) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 Crystallization method and bioavailability
EP2281558A1 (en) * 2009-08-06 2011-02-09 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compounds of O-Desmethyl-Tramadol and COX-inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
BR112012008075A2 (en) 2009-08-26 2016-03-01 Novartis Ag tetrasubstituted heteroaryl compounds and their use as mdm2 and / or mdm4 modulators
KR20120092586A (en) 2009-09-04 2012-08-21 노파르티스 아게 Bipyridines useful for the treatment of proliferative diseases
CA2772265A1 (en) 2009-09-04 2011-03-10 Novartis Ag Pyrazinylpyridines useful for the treatment of proliferative diseases
CA2771568A1 (en) 2009-09-04 2011-03-10 Novartis Ag Heteroaryl compounds as kinase inhibitors
EP2475661B1 (en) 2009-09-10 2013-10-23 Novartis AG Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer
AU2010294209A1 (en) 2009-09-10 2012-03-29 Irm Llc Ether derivatives of bicyclic heteroaryls
EP2325172A1 (en) * 2009-11-02 2011-05-25 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of celecoxib and L-proline
NZ599565A (en) 2009-11-04 2013-05-31 Novartis Ag Heterocyclic sulfonamide derivatives useful as mek inhibitors
CN102712589B (en) 2009-11-17 2015-05-13 诺华股份有限公司 Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
EP2516437B1 (en) 2009-12-21 2014-01-29 Novartis AG Disubstituted heteroaryl-fused pyridines
EP2516439B1 (en) 2009-12-21 2014-01-22 Novartis AG Diaza-spiro[5.5]undecanes as orexin receptor antagonists
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CA2785341A1 (en) 2009-12-31 2011-07-07 Novartis Ag Pyrazine derivatives and their use in the treatment of neurological disorders
JP2013518085A (en) 2010-02-01 2013-05-20 ノバルティス アーゲー Pyrazolo [5,1b] oxazole derivatives as CRF-1 receptor antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
CN102753527B (en) 2010-02-02 2014-12-24 诺华股份有限公司 Cyclohexyl amide derivatives as crf receptor antagonists
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
US8513236B2 (en) 2010-02-03 2013-08-20 Laurus Labs Private Limited Pterostilbene cocrystals
UY33236A (en) 2010-02-25 2011-09-30 Novartis Ag DIMERIC INHIBITORS OF THE IAP
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
AR082453A1 (en) 2010-04-21 2012-12-12 Novartis Ag FUROPIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME
CN102933205B (en) * 2010-04-28 2014-08-13 诺弗米克斯有限公司 Cilostazol cocrystals and compositions
US20130053381A1 (en) 2010-05-20 2013-02-28 Novartis Ag 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives
EP2582681A1 (en) 2010-06-17 2013-04-24 Novartis AG Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CN102947274A (en) 2010-06-17 2013-02-27 诺瓦提斯公司 Biphenyl substituted 1,3-dihydro-benzimidazol-2-ylideneamine derivatives
UY33469A (en) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag COMPOSITIONS AND METHODS TO MODULATE THE WNT SIGNALING ROAD
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
JP5128019B1 (en) 2010-07-13 2013-01-23 ノバルティス アーゲー Oxazine derivatives and their use in the treatment of neurological disorders
HRP20170617T1 (en) 2010-07-14 2017-06-30 Novartis Ag HETEROCYCLIC COMPOUNDS AS IP-RECEPTOR AGONISTS
EA201300160A1 (en) 2010-07-22 2013-06-28 Новартис Аг 2,3,5-Trisulfonated TIOPHENES AND THEIR APPLICATION
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
SG188438A1 (en) 2010-09-13 2013-05-31 Novartis Ag Triazine-oxadiazoles
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
TWI541244B (en) 2010-09-20 2016-07-11 福倫製藥股份有限公司 Imidazotriazinone compounds
EA201390532A1 (en) 2010-10-08 2013-09-30 Новартис Аг COMPOSITIONS OF NS3 SULFAMIDE INHIBITORS CONTAINING VITAMIN E
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
UY33794A (en) 2010-12-13 2012-07-31 Novartis Ag DIMERIC INHIBITORS OF THE IAP
WO2012080260A1 (en) 2010-12-13 2012-06-21 Novartis Ag Dimeric iap inhibitors
CU24152B1 (en) 2010-12-20 2016-02-29 Irm Llc 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS
CN103391937A (en) 2010-12-20 2013-11-13 Irm责任有限公司 Compositions and methods for modulating farnesoid x receptors
US20130274294A1 (en) 2010-12-20 2013-10-17 David Carcache 4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters
JP2014500318A (en) 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Compositions and methods for modulating farnesoid X receptor
US20120165331A1 (en) 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
EA023259B1 (en) 2011-01-04 2016-05-31 Новартис Аг Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
JP2014505688A (en) 2011-01-12 2014-03-06 ノバルティス アーゲー Oxazine derivatives and their use in the treatment of neurological disorders
AU2012206561B2 (en) 2011-01-13 2015-12-17 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders
WO2012095521A1 (en) 2011-01-13 2012-07-19 Novartis Ag Bace-2 inhibitors for the treatment of metabolic disorders
WO2012098501A1 (en) * 2011-01-21 2012-07-26 Ranbaxy Laboratories Limited Febuxostat co-crystals
WO2012101058A1 (en) 2011-01-24 2012-08-02 Novartis Ag 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
PL2670753T3 (en) 2011-01-31 2017-05-31 Novartis Ag Novel heterocyclic derivatives
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
WO2012120469A1 (en) 2011-03-08 2012-09-13 Novartis Ag Fluorophenyl bicyclic heteroaryl compounds
EP2688575B1 (en) 2011-03-24 2016-03-23 University of South Florida Lithium compositions
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
CN103619862A (en) 2011-04-14 2014-03-05 诺瓦提斯公司 Glycoside derivatives and uses thereof
ES2429348T3 (en) * 2011-04-28 2013-11-14 Zentiva, K.S. Pharmaceutically acceptable co-crystals of N- [2- (7-methoxy-1-naphthyl) ethyl] acetamide and processes for its preparation
UY34072A (en) 2011-05-17 2013-01-03 Novartis Ag INDOL SUBSTITUTED DERIVATIVES
UY34094A (en) 2011-05-27 2013-01-03 Novartis Ag DERIVATIVES OF PIPERIDINE 3-ESPIROCYCLIC AS AGRONISTS OF GHRELINE RECEPTORS
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EA201490228A1 (en) 2011-07-08 2014-08-29 Новартис Аг NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
PT2729142T (en) 2011-07-08 2018-10-01 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
MX2014000338A (en) 2011-07-08 2014-05-01 Novartis Ag Novel pyrrolo pyrimidine derivatives.
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
ES2551923T3 (en) 2011-07-27 2015-11-24 Novartis Ag Pyrazoline derivatives and their use as selective androgen receptor modulators
UY34278A (en) 2011-08-25 2013-04-05 Novartis Ag NEW NOXEDINE DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF DISEASES
CN104024254A (en) 2011-09-01 2014-09-03 Irm责任有限公司 Compounds and compositions as c-kit kinase inhibitors
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
AP2014007493A0 (en) 2011-09-01 2014-03-31 Irm Llc Compounds and compositions as C-KIT kinase inhibitors
KR20140071384A (en) 2011-09-01 2014-06-11 아이알엠 엘엘씨 Compounds and compositions as c-kit kinase inhibitors
EA201490542A1 (en) 2011-09-01 2014-08-29 АйАрЭм ЭлЭлСи COMPOUNDS AND COMPOSITIONS AS A PDGFR KINASE INHIBITOR
JO3192B1 (en) 2011-09-06 2018-03-08 Novartis Ag Benzothiazolone compound
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
ES2558457T3 (en) 2011-09-16 2016-02-04 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
TW201321353A (en) 2011-10-08 2013-06-01 Novartis Ag Carbamate/urea derivatives
JP2014532066A (en) 2011-10-13 2014-12-04 ノバルティス アーゲー Oxazine derivatives and their use in the treatment of neurological disorders
TWI580442B (en) 2011-10-19 2017-05-01 傑特大學 Pharmaceutical nanosuspension
JP2014530851A (en) 2011-10-21 2014-11-20 ノバルティスアーゲー Quinazoline derivatives as PI3K modulators
CA2853256C (en) 2011-10-28 2019-05-14 Novartis Ag Novel purine derivatives and their use in the treatment of disease
ES2606630T3 (en) 2011-11-28 2017-03-24 Novartis Ag Novel trifluoromethyl oxadiazole derivatives and their use in the treatment of disease
JP5992054B2 (en) 2011-11-29 2016-09-14 ノバルティス アーゲー Pyrazolopyrrolidine compound
IN2014CN04174A (en) 2011-12-22 2015-09-04 Novartis Ag
US20150148377A1 (en) 2011-12-22 2015-05-28 Novartis Ag Quinoline Derivatives
UY34572A (en) 2012-01-13 2013-09-02 Novartis Ag AGONIST HETEROCYCLIC COMPOUNDS OF THE IP RECEIVER
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105063A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20140357641A1 (en) 2012-01-13 2014-12-04 Novartis Ag IP receptor agonist heterocyclic compounds
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US20140350034A1 (en) 2012-01-27 2014-11-27 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
WO2013111108A1 (en) 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
UY34646A (en) 2012-03-02 2013-10-31 Novartis Ag ESPIROHIDANTOINE COMPOUNDS AND THEIR USE AS SELECTIVE MODULATORS OF THE ANDROGEN RECEIVER
HK1206726A1 (en) 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
WO2013163508A1 (en) 2012-04-27 2013-10-31 Novartis Ag Tetrahydropyran dgat1 inhibitors
ES2624291T3 (en) 2012-04-27 2017-07-13 Novartis Ag DGAT1 cyclic ether bond inhibitors
TW201348235A (en) 2012-05-03 2013-12-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
PT2855456T (en) 2012-05-04 2017-07-10 Novartis Ag Complement pathway modulators and uses thereof
UY34807A (en) 2012-05-16 2013-12-31 Novartis Ag MONOCYCLIC DERIVATIVES OF HETEROARYL CYCLOALKYL-DIAMINE
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
WO2013184766A1 (en) 2012-06-06 2013-12-12 Irm Llc Compounds and compositions for modulating egfr activity
AU2013276138B2 (en) * 2012-06-15 2017-02-23 Basf Se Multicomponent crystals comprising Dasatinib and selected cocrystal formers
WO2013192345A1 (en) 2012-06-20 2013-12-27 Novartis Ag Complement pathway modulators and uses thereof
EP2864313A1 (en) 2012-06-22 2015-04-29 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
AU2013282768A1 (en) 2012-06-28 2015-01-22 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JP6154897B2 (en) 2012-06-28 2017-06-28 ノバルティス アーゲー Pyrrolidine derivatives and their use as complement pathway regulators
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EP2867227B1 (en) 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
EA201590200A1 (en) 2012-07-12 2015-08-31 Новартис Аг MODULATORS OF THE COMPLEMENT ACTIVATION WAY AND THEIR APPLICATION
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
KR101303803B1 (en) 2012-08-02 2013-09-04 순천향대학교 산학협력단 Preparation of co-crystals of various drug substances including cabamazepine-saccharin co-crystals by anti-solvent method
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
AU2013303824B2 (en) 2012-08-13 2016-03-31 Elanco Tiergesundheit Ag Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (SYK)
BR112015004127A2 (en) 2012-08-30 2017-07-04 Novartis Ag salts of benzothiazolone compound as beta-2-adrenoreceptor agonist
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
EP2890704B1 (en) 2012-08-31 2018-02-28 Novartis AG 2'-ethynyl nucleoside derivatives for treatment of viral infections
US9447039B2 (en) 2012-09-07 2016-09-20 Novartis Ag Indole carboxamide derivatives and uses thereof
MX2015003535A (en) 2012-09-19 2015-07-14 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors.
EP2900237A1 (en) 2012-09-25 2015-08-05 Novartis AG Compounds for use in gastric complication
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
EP2900684A2 (en) 2012-09-29 2015-08-05 Novartis AG Cyclic peptides and use as medicines
EP2909181B1 (en) 2012-10-16 2017-08-09 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
EP2917205A1 (en) 2012-11-07 2015-09-16 Novartis AG Substituted indole derivatives
US9296733B2 (en) * 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
WO2014078813A1 (en) 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
TWI600654B (en) 2012-11-19 2017-10-01 艾姆公司 Compounds and compositions for the treatment of parasitic diseases
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
ES2709034T3 (en) 2012-12-13 2019-04-12 Novartis Ag Pyrimido [4,5-b] quinoline-4,5 (3h, 10h) -diones as suppressors of nonsense mutations
PL2931716T3 (en) 2012-12-13 2017-04-28 Novartis Ag Pyridone derivatives and uses thereof in the treatment of tuberculosis
WO2014097147A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
PE20151067A1 (en) 2012-12-19 2015-08-05 Novartis Ag AUTOTAXIN INHIBITORS
ES2628369T3 (en) 2012-12-19 2017-08-02 Novartis Ag Tricyclic compounds to inhibit the CFTR channel
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
MX367525B (en) 2013-02-14 2019-08-26 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors.
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
WO2014132205A1 (en) 2013-02-28 2014-09-04 Novartis Ag Formulation comprising benzothiazolone compound
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN105229003B (en) 2013-03-14 2017-03-15 诺华股份有限公司 2- (1H-indol-4-ylmethyl) -3H-imidazo [4,5-B ] pyridine-6-carbonitrile derivatives as complement factor B inhibitors for the treatment of ophthalmic diseases
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
UY35400A (en) 2013-03-15 2014-10-31 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections
WO2014167528A1 (en) 2013-04-11 2014-10-16 Novartis Ag Spiropyrazolopyridine derivatives and uses thereof for the treatment of viral infections
EP2991999B1 (en) 2013-04-29 2019-05-08 Mapi Pharma Limited Dapagliflozin lactose co-crystal
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
WO2014191894A1 (en) 2013-05-27 2014-12-04 Novartis Ag Imidazopyrrolidinone derivatives and their use in the treatment of disease
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
KR20160012197A (en) 2013-05-28 2016-02-02 노파르티스 아게 Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
US9624247B2 (en) 2013-05-28 2017-04-18 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
JO3425B1 (en) 2013-07-15 2019-10-20 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors
US20160168119A1 (en) 2013-07-18 2016-06-16 Novartis Ag Autotaxin inhibitors
EA035256B1 (en) 2013-07-18 2020-05-21 Новартис Аг Autotaxin inhibitors comprising a heteroaryl-benzyl-amide core
JP6461150B2 (en) 2013-07-31 2019-01-30 ノバルティス アーゲー 1,4-disubstituted pyridazine derivatives and their use to treat conditions associated with SMN deficiency
EP3060563B1 (en) 2013-10-25 2018-05-02 Novartis AG Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
EP3089963A1 (en) 2013-10-30 2016-11-09 Novartis AG 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
CN105658646B (en) 2013-11-01 2018-11-27 诺华股份有限公司 Aminoheteroaryl benzamide as kinase inhibitor
WO2015070177A2 (en) * 2013-11-11 2015-05-14 Collaborative Medicinal Development, Llc Metal complexes and methods of treatment
EP3071571A1 (en) 2013-11-21 2016-09-28 Novartis AG Pyrrolopyrrolone derivatives and their use as bet inhibitors
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
CA2930614A1 (en) 2013-12-17 2015-06-25 Novartis Ag Cytotoxic peptides and conjugates thereof
RS58053B1 (en) 2013-12-19 2019-02-28 Novartis Ag [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
AU2014369180B2 (en) 2013-12-20 2016-11-17 Novartis Ag Heteroaryl butanoic acid derivatives as LTA4H inhibitors
WO2015102929A1 (en) 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
AU2015236369B2 (en) 2014-03-24 2017-02-16 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
ES2787625T3 (en) 2014-04-17 2020-10-16 Novartis Ag Polycyclic hERG activators
JP6514716B2 (en) 2014-04-22 2019-05-15 ノバルティス アーゲー Isoxazoline hydroxamic acid derivatives as LpxC inhibitors
WO2015162558A1 (en) 2014-04-24 2015-10-29 Novartis Ag Autotaxin inhibitors
MX2016013981A (en) 2014-04-24 2016-11-15 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors.
KR20160141855A (en) 2014-04-24 2016-12-09 노파르티스 아게 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160141856A (en) 2014-04-24 2016-12-09 노파르티스 아게 Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
HUE067954T2 (en) 2014-05-13 2024-11-28 Novartis Ag Compounds and compositions for inducing chondrogenesis
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
TWI714528B (en) 2014-05-14 2021-01-01 瑞士商諾華公司 Carboxamide derivatives
US20170088545A1 (en) 2014-05-14 2017-03-30 Novartis Ag Carboxamide inhibitors
US20170088546A1 (en) 2014-05-14 2017-03-30 Novartis Ag Carboxamide inhibitors
SI3149001T1 (en) 2014-05-28 2019-08-30 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
CN106414443B (en) 2014-06-03 2018-10-26 诺华股份有限公司 Pyridopyrimidine dione derivative
US10138232B2 (en) 2014-06-03 2018-11-27 Novartis Ag Naphthyridinedione derivatives
US9896448B2 (en) 2014-06-03 2018-02-20 Novartis Ag Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives
AU2015273098B2 (en) 2014-06-13 2018-05-10 Novartis Ag Auristatin derivatives and conjugates thereof
TW201625586A (en) 2014-07-02 2016-07-16 諾華公司 Cyclohexen-1-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
TW201625584A (en) 2014-07-02 2016-07-16 諾華公司 Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
TW201625601A (en) 2014-07-02 2016-07-16 諾華公司 Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
CN107001316A (en) 2014-08-06 2017-08-01 诺华股份有限公司 It is used as the Carbostyril derivative of antiseptic
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
WO2016038582A1 (en) 2014-09-12 2016-03-17 Novartis Ag Compounds and compositions as raf kinase inhibitors
ES2844211T3 (en) 2014-09-12 2021-07-21 Novartis Ag Compounds and compositions as kinase inhibitors
WO2016049266A1 (en) * 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
WO2016079669A1 (en) 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
WO2016088082A1 (en) 2014-12-05 2016-06-09 Novartis Ag Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
HUE047225T2 (en) 2014-12-16 2020-04-28 Novartis Ag Isoxazole hydroxamic acid compounds as lpxc inhibitors
UA120945C2 (en) 2014-12-23 2020-03-10 Новартіс Аг TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR APPLICATIONS
US10189813B2 (en) 2015-03-25 2019-01-29 Novartis Ag Formylated N-heterocyclic derivatives as FGFR4 inhibitors
ES2876974T3 (en) 2015-04-07 2021-11-15 Novartis Ag Combination therapy with chimeric antigen receptor and amino pyrimidine derivatives
WO2016174616A1 (en) 2015-04-30 2016-11-03 Novartis Ag Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
US10421770B2 (en) * 2015-06-19 2019-09-24 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
CA2989001A1 (en) * 2015-06-25 2016-12-29 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof
EP3352822B1 (en) 2015-09-24 2022-07-27 Pain Therapeutics, Inc. Cocrystals of naloxone and naltrexone
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
US20200289514A1 (en) 2015-11-13 2020-09-17 Novartis Ag Novel Pyrazolo Pyrimidine Derivatives
PL3757097T3 (en) 2015-11-26 2022-07-25 Novartis Ag Diamino pyridine derivatives
CN105399664A (en) * 2015-12-11 2016-03-16 吉林大学珠海学院 Deferiprone pharmaceutical cocrystal with 2,5-dihydroxybenzoic acid as precursor and preparation method thereof
CN105541701A (en) * 2015-12-11 2016-05-04 吉林大学珠海学院 Pharmaceutical cocrystal of deferiprone with maleic acid as precursor, and preparation method thereof
CN105399665A (en) * 2015-12-11 2016-03-16 吉林大学珠海学院 Deferiprone pharmaceutical cocrystal with p-hydroxybenzoic acid as precursor and preparation method thereof
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
EP3390386A1 (en) 2015-12-18 2018-10-24 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
AU2016371387B2 (en) 2015-12-18 2019-11-14 Novartis Ag Tricyclic compounds and compositions as kinase inhibitors
AU2017208948A1 (en) 2016-01-21 2018-08-09 Novartis Ag Compounds and compositions for the treatment of cryptosporidiosis
JP7016809B2 (en) 2016-02-19 2022-02-07 ノバルティス アーゲー Tetracyclic pyridone compound as an antiviral agent
WO2017149463A1 (en) 2016-03-01 2017-09-08 Novartis Ag Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
US10858366B2 (en) 2016-03-08 2020-12-08 Novartis Ag Tricyclic compounds useful to treat orthomyxovirus infections
US9988416B2 (en) 2016-03-24 2018-06-05 Novartis Ag Alkynyl nucleoside analogs as inhibitors of human rhinovirus
WO2017175185A1 (en) 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
IL263429B (en) 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of a triazolopyrimidine compound
US10676479B2 (en) 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
EP3472161B1 (en) 2016-06-20 2020-03-25 Novartis AG Triazolopyridine compounds and uses thereof
CN106432136B (en) * 2016-06-30 2018-12-25 中国药科大学 A kind of Hydrochioro and atenolol are total to unformed system and preparation method thereof
PL3971177T3 (en) 2016-07-20 2024-10-28 Novartis Ag Aminopyridine derivatives and their use as selective alk-2 inhibitors
JOP20170169A1 (en) 2016-08-29 2019-01-30 Novartis Ag Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
TW201811766A (en) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
WO2018047081A1 (en) 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
WO2018047109A1 (en) 2016-09-09 2018-03-15 Novartis Ag Polycyclic pyridone compounds as antivirals
JOP20190053A1 (en) 2016-09-23 2019-03-21 Novartis Ag Aza-indazole compounds for use in tendon and/or ligament injuries
MY196425A (en) 2016-09-23 2023-04-10 Novartis Ag Indazole Compounds For Use In Tendon And/Or Ligament Injuries
JOP20190061A1 (en) 2016-09-28 2019-03-26 Novartis Ag Beta-lactamase inhibitors
WO2018073753A1 (en) 2016-10-18 2018-04-26 Novartis Ag Fused tetracyclic pyridone compounds as antivirals
CA3043575A1 (en) 2016-11-10 2018-05-17 Novartis Ag Bmp potentiators
WO2018141749A1 (en) 2017-02-01 2018-08-09 Medivir Ab Therapeutic applications of malt1 inhibitors
EA201992233A1 (en) 2017-03-24 2020-02-21 Новартис Аг COMPOUNDS OF ISOXOXOLICARBOXAMIDE AND THEIR APPLICATION
AR111419A1 (en) 2017-04-27 2019-07-10 Novartis Ag INDAZOL PIRIDONA FUSIONED COMPOUNDS AS ANTIVIRALS
AR111658A1 (en) 2017-05-05 2019-08-07 Novartis Ag 2-TRICYCLINAL CHINOLINONES AS ANTIBACTERIAL AGENTS
UY37774A (en) 2017-06-19 2019-01-31 Novartis Ag SUBSTITUTED 5-CYANOINDOL COMPOUNDS AND USES OF THE SAME
WO2019087163A1 (en) 2017-11-06 2019-05-09 Novartis Ag Polycyclic herg activators
WO2019087162A1 (en) 2017-11-06 2019-05-09 Novartis Ag Polycyclic herg activators
JP2021503458A (en) 2017-11-17 2021-02-12 ノバルティス アーゲー New dihydroisoxazole compounds and their use for the treatment of hepatitis B
EA202091293A1 (en) 2017-11-24 2020-11-23 Новартис Аг PYRIDINONE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS
CN111433210A (en) 2017-12-20 2020-07-17 诺华股份有限公司 Fused tricyclic pyrazolo-dihydropyrazinyl-pyridinone compounds as antiviral agents
EP3730141A4 (en) 2017-12-21 2021-10-13 Kyorin Pharmaceutical Co., Ltd. THERAPEUTIC AGENT FOR NOCTURAL POLLAKIURIA
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
EP3755683A1 (en) * 2018-02-23 2020-12-30 Center for Intelligent Research in Crystal Engineering, S.L. Cocrystals of ubiquinol and compositions comprising them
WO2019166951A1 (en) 2018-02-28 2019-09-06 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
CN118878544A (en) 2018-02-28 2024-11-01 诺华股份有限公司 Compounds as inhibitors of orthomyxovirus replication for the treatment of influenza
MY206521A (en) 2018-05-22 2024-12-19 Js Innomed Holdings Ltd Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PE20210780A1 (en) 2018-06-19 2021-04-21 Novartis Ag CYANOTRIAZOLE COMPOUNDS AND USES OF THEM
GB201811825D0 (en) 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
US11040038B2 (en) 2018-07-26 2021-06-22 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
BR112021002632A2 (en) 2018-08-17 2021-05-11 Novartis Ag urea compounds and compositions as smarca2/brm atpase inhibitors
GB201813791D0 (en) 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
TWI838401B (en) 2018-09-12 2024-04-11 瑞士商諾華公司 Antiviral pyridopyrazinedione compounds
MX2021003294A (en) 2018-09-21 2021-07-15 Novartis Ag Isoxazole carboxamide compounds and uses thereof.
TW202028208A (en) * 2018-10-09 2020-08-01 瑞士商諾華公司 N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide solid forms
JP2022514253A (en) 2018-12-18 2022-02-10 ノバルティス アーゲー N- (Pyridine-2-ylsulfonyl) cyclopropanecarboxamide derivative and its use in the treatment of CFTR-mediated diseases
MX2021008303A (en) 2019-01-11 2021-10-13 Novartis Ag LTA4H INHIBITORS FOR THE TREATMENT OF HYDRADENITIS SUPPURATIVA.
EP3911652A1 (en) 2019-01-18 2021-11-24 Biogen MA Inc. Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
WO2020154581A1 (en) * 2019-01-24 2020-07-30 Assia Chemical Industries Ltd Solid state forms of fedovapagon-salicyclic acid co-crystal
MX2021011289A (en) 2019-03-22 2021-11-03 Sumitomo Pharma Oncology Inc Compositions comprising pkm2 modulators and methods of treatment using the same.
WO2020250116A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
PE20220578A1 (en) 2019-06-27 2022-04-20 Biogen Ma Inc IMIDAZO[1,2-A]PYRIDINIL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
JOP20210324A1 (en) 2019-06-27 2023-01-30 Biogen Ma Inc Derivatives of 2H-Indazole and their use in the treatment of disease
EP4021572A1 (en) 2019-08-28 2022-07-06 Novartis AG Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
WO2021044351A1 (en) 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors
EP4034537A1 (en) 2019-09-26 2022-08-03 Novartis AG Antiviral pyrazolopyridinone compounds
JP2021054781A (en) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド Co-crystalline efinaconazole and method for producing the same
TW202130631A (en) 2019-12-18 2021-08-16 瑞士商諾華公司 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN115297863A (en) 2020-01-22 2022-11-04 博善人工智能生物科技有限公司 Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds
EP4093376A1 (en) 2020-01-22 2022-11-30 BenevolentAI Bio Limited Pharmaceutical compositions and their uses
EP3884938A1 (en) 2020-03-25 2021-09-29 ArtemiFlow GmbH 1,2,4-trioxane compounds and compositions comprising the same for use in the treatment of covid-19
WO2021214080A1 (en) 2020-04-20 2021-10-28 Novartis Ag Antiviral 1,3-di-oxo-indene compounds
TWI832045B (en) 2020-04-20 2024-02-11 瑞士商諾華公司 Antiviral 1,3-di-oxo-indene compounds
CN113582927B (en) * 2020-04-30 2023-07-04 苏州恩华生物医药科技有限公司 Celecoxib and pregabalin co-amorphous substance and preparation method thereof
AU2021272972A1 (en) 2020-05-13 2022-12-08 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
WO2021253180A1 (en) 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
AR122613A1 (en) 2020-06-16 2022-09-21 Novartis Ag METHYL 2-METHYL-5-OXO-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS
GEP20257771B (en) 2020-09-17 2025-06-10 Novartis Ag Compounds and compositions as sppl2a inhibitors
CN112552189A (en) * 2020-11-10 2021-03-26 中国海洋大学 Pharmaceutical co-crystal of amantadine hydrochloride and resveratrol and preparation method thereof
CN112521292B (en) * 2020-12-18 2022-02-11 深圳市萱嘉生物科技有限公司 Eutectic crystal of betaine and organic acid and preparation method and application thereof
US20250268877A1 (en) 2020-12-22 2025-08-28 Biogen Ma Inc. 2h-indazole derivatives as irak4 inhibitors and their use in the treatment of disease
MX2023007511A (en) 2020-12-22 2023-09-08 Biogen Ma Inc Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease.
EP4274832A1 (en) 2021-01-07 2023-11-15 Biogen MA Inc. Tyk2 inhibitors
EP4308559A1 (en) 2021-03-15 2024-01-24 Novartis AG Benzisoxazole derivatives and uses thereof
UY39671A (en) 2021-03-15 2022-10-31 Novartis Ag Pyrazolopyridine derivatives and their uses.
AR125196A1 (en) 2021-03-26 2023-06-21 Novartis Ag 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND THEIR USES
WO2022217232A1 (en) 2021-04-10 2022-10-13 Sunovion Pharmaceuticals Inc. Chromans and benzofurans as 5-ht1a and taar1 agonists
JP2024513918A (en) 2021-04-10 2024-03-27 サノビオン ファーマシューティカルズ インク Substituted sulfonamide-chroman compounds and pharmaceutical compositions and methods of use thereof
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
WO2022234287A1 (en) 2021-05-06 2022-11-10 Benevolentai Bio Limited Imidazopyridazine derivatives useful as trk inhibitors
AR125966A1 (en) 2021-05-26 2023-08-30 Novartis Ag NEW BICYCLIC COMPOUNDS AND THEIR USES
WO2022254362A1 (en) 2021-06-03 2022-12-08 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof
US12005134B2 (en) 2021-06-30 2024-06-11 Abe Pharmaceutical Composition for stimulating facial hair growth and methods of manufacturing a composition for stimulating facial hair growth
WO2023275796A1 (en) 2021-07-01 2023-01-05 Novartis Ag Heterocyclic derivatives as sphingosine-1-phosphate 3 inhibitors
CN117980292A (en) 2021-07-22 2024-05-03 诺华股份有限公司 Substituted pyridone compounds for treating orthomyxovirus infections
CA3233074A1 (en) 2021-09-23 2023-03-30 Sumitomo Pharma America, Inc. Methods of treating metabolic disorders
CN113845438B (en) * 2021-10-12 2023-02-21 河北大学 A kind of paracetamol-piracetam medicine co-crystal and preparation method thereof
IL312891A (en) 2021-11-17 2024-07-01 Chdi Foundation Inc HTT modulators for the treatment of Huntington's disease
AR127698A1 (en) 2021-11-23 2024-02-21 Novartis Ag NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
CN114031515B (en) * 2021-11-29 2022-10-21 河北大学 Acetaminophen-ibuprofen pharmaceutical co-crystal and preparation method thereof
US20250051345A1 (en) 2021-12-13 2025-02-13 Novartis Ag Pyridine-3-carboxylate compounds as cav1.2 activators
EP4469157A1 (en) 2022-01-24 2024-12-04 Novartis AG Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
CN114644669B (en) * 2022-03-10 2025-01-03 华润紫竹药业有限公司 A preparation method of progesterone co-crystal and its application
CN119137099A (en) 2022-04-01 2024-12-13 诺华股份有限公司 Complement factor B inhibitors and uses thereof
CN114835657A (en) * 2022-06-10 2022-08-02 大连工业大学 Method for regulating and controlling ethenzamide-saccharin eutectic crystal polycrystalline type based on ionic liquid
WO2024006493A1 (en) 2022-07-01 2024-01-04 Biogen Ma Inc. Tyk2 inhibitors
UY40374A (en) 2022-08-03 2024-02-15 Novartis Ag NLRP3 INFLAMASOME INHIBITORS
TW202417450A (en) 2022-10-12 2024-05-01 瑞士商諾華公司 Tricyclic compounds and their uses
EP4619104A1 (en) 2022-11-16 2025-09-24 Novartis AG Bicyclic heterocycles and their use as wrn inhibitors
EP4618991A1 (en) 2022-11-18 2025-09-24 Novartis AG Pharmaceutical combinations and uses thereof
TW202440563A (en) 2022-11-28 2024-10-16 美商住友製藥美國公司 2-phenylmorpholine and 2-phenyl(thio)morpholine compounds and uses thereof
EP4647431A1 (en) 2023-01-04 2025-11-12 Gan & lee Pharm Co., Ltd. Compound and method for targeted degradation of androgen receptor
CN116162053B (en) * 2023-01-10 2025-01-14 山东省分析测试中心 Gliclazide-piperazine eutectic crystal and preparation method thereof
WO2024176131A1 (en) 2023-02-23 2024-08-29 Novartis Ag Tead- and kras g12d-inhibitor combinations for treating cancer
WO2024176130A1 (en) 2023-02-23 2024-08-29 Novartis Ag Tead- and her2-inhibitor combinations for treating cancer
AU2024253757A1 (en) 2023-04-07 2025-10-16 Biogen Ma Inc. 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases
WO2024218275A1 (en) * 2023-04-20 2024-10-24 Institut Gustave Roussy Liquid and solid compositions of imipridone derivatives
TW202506103A (en) 2023-04-24 2025-02-16 瑞士商諾華公司 Antiviral 1,3-di-oxo-indene compounds
US20240391941A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder
WO2025068951A1 (en) 2023-09-29 2025-04-03 Novartis Ag Complement factor b inhibitors and uses thereof
US20250263416A1 (en) 2024-02-15 2025-08-21 Incyte Corporation SPPL2a INHIBITORS
CN118078830B (en) * 2024-03-13 2025-09-23 海南海和制药有限公司 A method for preparing a pharmaceutical composition containing fluorouracil
WO2025215527A2 (en) 2024-04-10 2025-10-16 Novartis Ag Pharmaceutical combinations and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042222A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Polymorphic crystalline forms of celecoxib
WO2001042221A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Solid-state form of celecoxib having enhanced bioavailability
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2003033462A2 (en) * 2001-10-15 2003-04-24 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500862D0 (en) * 1985-01-14 1985-02-20 Tate & Lyle Plc Composition
AU2003272270A1 (en) * 2003-02-28 2004-09-28 The Regents Of The University Of Michigan Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042222A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Polymorphic crystalline forms of celecoxib
WO2001042221A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Solid-state form of celecoxib having enhanced bioavailability
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2003033462A2 (en) * 2001-10-15 2003-04-24 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEISSBUCH I ET AL: "Understanding and control of nucleation, growth, habit, dissolution and structure of two- and three-dimensional crystals using 'tailor-made' auxiliaries", 1995, ACTA CRYSTALLOGRAPHICA. SECTION B, STRUCTURAL SCIENCE, MUNKSGAARD, COPENHAGEN, DK, PAGE(S) 115-148, ISSN: 0108-7681, XP002960386 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9161912B2 (en) 2008-12-23 2015-10-20 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9532993B2 (en) 2011-11-25 2017-01-03 Nuformix Limited Aprepitant L-proline solvates—compositions and cocrystals
US9440957B2 (en) 2012-06-06 2016-09-13 Novartis Ag Compounds and compositions for modulating EGFR Activity
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof

Also Published As

Publication number Publication date
CA2514733A1 (en) 2004-09-16
JP2007524596A (en) 2007-08-30
WO2004078163A2 (en) 2004-09-16
EP1631260A2 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
WO2004078163A3 (en) Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003272270A1 (en) Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
BR9914858A (en) Prostaglandin endoperoxide biosynthesis inhibitors h
BRPI0613371B8 (en) cartridge for the storage and release of a two-phase compound
HN2002000156A (en) BENZAMIDE THIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT THE PROLIFERATION OF CELLS AND METHODS FOR THEIR USE.
CL2003002611A1 (en) COMPOUNDS DERIVED FROM THE HYDROXAMIC THIOPHEN ACID, 2-HYDROXAMIDE-5 - [(ARIL OR HETEROARIL) -DISUTITUTED-METHYL] -AMIDE OF THE THYMPHENE-2,5-DICARBOXYL DYNAMIC ACID, PHARMACEUTICAL COMPOSITION FOR PREPARATION AND USE D
Geurs et al. The zinc-binding group effect: lessons from non-hydroxamic acid vorinostat analogs
BRPI0907414A2 (en) oral dosage form containing at least two medicinal products
ATE432972T1 (en) MULTI-COMPONENT THIN-TO-THICK SYSTEM
Zheng-Nan et al. Prodrugs of hydrogen sulfide and related sulfur species: recent development
AR052523A1 (en) PHARMACEUTICAL COMPOSITIONS OF AN NON-STEROID ANTI-INFLAMMATORY PHARMACO
PL3927312T3 (en) Minimization of agglomeration, aeration and preservation of the coating of pharmaceutical compositions containing Ibuprofen
HK1085137A (en) Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TW200608889A (en) Agrochemical composition
ID26972A (en) TIOESTER ACID S-SUBSTITUTION 11β-BENZALDOXINS ESTRA-4,9-DIENACARBONATE, PROCESS FOR MAKING AND PHARMACEUTICAL PROPERTIES CONTAINED FROM THIS COMPOUND
MXPA06011467A (en) Active substance combination comprising a carbinol combined to at least an nsaid.
DK1943232T3 (en) Quadric acid derivatives as inhibitors of histone deacetylase
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
WO2006097460A8 (en) Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
Almarsson et al. Pharmaceutical co-crystal compositions
DK1963355T3 (en) Newly known cholest-4-ene-3-onoxime derivatives. pharmaceutical compositions which encompass the same, and process for their preparation
BR0211149A (en) Pharmaceutical preparations containing active substance loaded ion exchange resins
BR0304303B1 (en) Composition for a low viscosity hydrophobic thickening system for the thickening of an aqueous polymer containing system, and methods for providing a low viscosity thickening system for an aqueous polymer containing system and for increasing the viscosity of an aqueous polymer containing system
BRPI0702769A (en) naphthalene compounds, processes for their preparation and pharmaceutical compositions containing them
Mitchell Xenobiotic C-sulfonate derivatives; metabolites or metabonates?

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2514733

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007059356

Country of ref document: US

Ref document number: 10546963

Country of ref document: US

Ref document number: 2006508979

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004715190

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004715190

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10546963

Country of ref document: US